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Abstract: Seventeen drimanes including polygodial (1), isopolygodial (2), drimenol (3) 
and confertifolin (4) obtained from natural sources and the semi-synthetic derivatives 5–17 
obtained from 1–3, were evaluated in vitro for antifungal properties against a unique panel 
of fungi with standardized procedures by using two end-points, MIC100 and MIC50. A SAR 
analysis of the whole series, supported by conformational and electronic studies, allowed 
us to show that the Δ7,8 -double bond would be one of the key structural features related to 
the antifungal activity. The MEPs obtained for active compounds exhibit a clear negative 
minimum value (deep red zone) in the vicinity of the Δ7,8 -double bond, which is not 
present in the inactive ones. Apart of this negative zone, a positive region (deep blue) 
appears in 1, which is not observed either in its epimer 2 nor in the rest of the active 
compounds. The LogP of active compounds varies between 2.33 and 3.84, but differences 
in MICs are not correlated with concomitant variations in LogP values. 
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1. Introduction 
In the course of our ongoing search for antifungal compounds from natural sources, we recently 
reported that the aerial parts of Polygonum acuminatum Kunth., used in the Argentinean traditional 
medicine for ailments related to fungal infections [1], possessed antifungal properties against yeasts 
and dermatophytes, these results supporting their ethnopharmacological use [2]. Polygodial (1, Figure 1) 
was isolated from the most active extract as the main compound responsible for the activity, although 
other drimane derivatives such as isopolygodial (2) drimenol (3) and confertifolin (4) (Figure 1) 
showed antifungal properties too [2]. 
Figure 1. Drimanes isolated from Polygonum acuminatum. 
 
Although the claims that 1 possesses antifungal activity were consistent in all previous reports [3–6], 
contradictory reports were found in the literature regarding the antifungal activities of its natural 
analogue 2, which was variously reported to be either active or inactive, and based on this information, 
conflicting opinions about the main structural features required for drimanes to display antifungal 
activities were put forth. They can be summarized as follows: Fujita and Kubo stated that the  
- orientation of the C-9 carbonyl group was indispensable for activity, since 1 (with an aldehyde in 
the C-9 orientation) but not 2 (with a C-9 aldehyde) possessed antifungal activity [7]. Conversely, 
Anke and Sterner [8] found that 2 did possess antifungal activity, although lower than that of 1, which 
was corroborated by us in the paper cited above [2] and in a subsequent one [9]. Another structural 
feature which was assigned a role in the antifungal activity was the ,-unsaturated C-8 aldehyde 
moiety which, according to Taniguchi et al., was essential for activity [10]. However, this appears to 
be a contradiction with their own previous report in which 2 was devoid of antifungal activity, 
although it possess the ,-unsaturated C-8 aldehyde moiety [7,10]. Fujita and Kubo also reported that 
1 lost its antifungal activity against Saccharomyces cerevisiae in certain media, because of formation 
of a pyrrole between its aldehydes and the amines present in the medium [7]. Considering that, with 
the formation of a pyrrole, both aldehydes disappear, this report opens a new question: if one or both 
aldehydes are necessary for the antifungal activity. 
In order to clarify the main features required for drimanes to display antifungal activities, we tested 
herein a series of 17 compounds 1–17 (most of them not previously assayed for antifungal activities) 
for antifungal properties against a unique panel of nine fungal strains, with a standardized 
methodology, in the same laboratory. To guarantee confident and reproducible results, the whole series 
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was tested following the Clinical and Laboratory Standards Institute (CLSI) [11,12] standardized 
procedures. CLSI has established consensus procedures to facilitate the agreement among laboratories 
in measuring the susceptibility of yeasts (updated in 2008 as M-27 A3) and of filamentous fungi 
(updated in 2008 as M-38 A2) to antifungal agents, with broth dilution methods. The standardized 
parameters detailed in both documents include protocols for the preparation of antifungal stock 
solutions, dilutions for testing, inocula, culture medium, temperature and incubation time, endpoint 
definitions and reference MIC ranges for microdilution testing of both, the established and newly 
introduced antifungal agents. 
Among the tested analogues of 1, compounds 2–4 were isolated from P. acuminatum leaves and the 
remaining compounds 5–17 were prepared by isomerization, reduction, oxidation and methylenation 
reactions using the natural compounds 1, 2 and 3 as starting materials. They were tested against three 
yeasts: Candida albicans, S. cerevisiae and Cryptococcus neoformans; three Aspergillus spp.  
(A. flavus, A. fumigatus and A. niger) and three dermatophytes: Microsporum gypseum, Trichophyton 
rubrum and Trichophyton mentagrophytes by using two end-points MIC100 and MIC50. A SAR 
analysis of the whole series, supported by conformational and electronic studies on some selected 
compounds is presented herein, with the aim of determining the stereo-electronic characteristics related 
to the antifungal behavior and thus contribute to the understanding of the structural properties of 
antifungal drimanes. 
2. Results and Discussion 
2.1. Chemistry 
Sesquiterpenes 1–4 were obtained from P. acuminatum leaves as described previously [2]. 
Compounds 1–3 were used as starting materials for the preparation of compounds 5–17.  
2.1.1. Compounds Obtained from 1 
Scheme 1 shows the modifications performed on compound 1 that led to compounds 5–8. 
Reduction of 1 with excess of NaBH4 in MeOH at rt produced (−)-(5S,10S)-(9R)-7-drimene-11,12-diol 
(5) and (−)-(5aS,9aS,9bR)-6,6,9a-trimethyl-1,3,5,5a,6,7,8,9,9a,9b-decahydronaphtho[1,2-c]furan (6). 
Isodrimeninol (7) was obtained by reduction of 1 with 0.5 mmol of NaBH4 for each mmol of drimane 
and compound 8 was a methylenation product obtained by treating 1 with one equivalent of the bulky 
Tebbe´s reagent, following previously reported procedures [13]. The identities of 5, 7 and 8 were 
established by comparison with previously reported data [13–16]. Compound 6, which was only 
previously reported once [16], is described in this work.  
2.1.2. Compounds Obtained from 2  
Scheme 2 shows the modifications performed on compound 2. Reduction of 2 with excess NaBH4 
in MeOH at r.t. produced (+)-(5S,10S)-(9S)-7-drimene-11,12 diol (isodrimendiol, 9) [17] which, by 
catalytic hydrogenolysis using Pd/C (10% Pd), was converted into isodrimenol 10 [15,18]. 
Epoxidation of 9 with m-chloroperbenzoic acid (MCPBA) produced a single epoxide 11 in 75% yield. 
The 7-H signal in the 1H-NMR spectrum (δ 3.3, brdd, J = 5.2 Hz, 5.2 Hz) [19] and the signal for C-5, 
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appearing at a δ 15.2 ppm lower than that corresponding to 9 in the 13C-NMR spectrum, confirmed the 
α configuration of 11, as reported for similar compounds [20]. The epoxide 11 was refluxed with 
LiAlH4 in THF to afford the triol 12 in 85% yield. Oxidative degradation of 12 with sodium periodate 
gave the ketol 13 in 75% yield [21]. 
Scheme 1. Modifications performed on 1 to obtain compounds 5–8. 
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Conditions and reagents: (1.a) Tebbe’s reagent (C5H5)2TiCH2ClAl(CH3)2; (1.b) NaBH4 (excess), 
MeOH rt; (1.c) NaBH4 (0.5 mmol per mmol of 1), MeOH rt. 
Scheme 2. Modifications performed on 2 to obtain compounds 9–13. 
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Conditions and reagents: (2.a) NaBH4 (excess), MeOH rt; (2.b) H2, Pd/C (10%); (2.c) MCPBA, 
DCM; (2.d) LiAlH4, THF; (2.e) NaIO4, THF/H2O. 
2.1.3. Compounds Obtained from 3 
Scheme 3 shows the modifications performed on 3. Oxidation of 3 with Jones reagent afforded 
drimenal 14 and the unsaturated ketone 15. On the other hand, the unsaturated ketone 16 was obtained 
by treating 3 with the oxidation reagent pyridinium chlorochromate (PCC) [14]. Their structures were 
determined by comparison with the previously reported data [14,22,23]. In addition, catalytic 
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hydrogenation of 3 using Pd/C (10% Pd), led to the saturated drimanol 17 whose spectroscopic data 
were in accordance to the literature [24]. 
Scheme 3. Modifications performed on 3 to obtain compounds 14–17. 
3.c
 
Conditions and reagents: (3.a): Jones reagent; (3.b): Pyridinium chlorochromate (PCC); (3.c) H2, 
Pd/C (10%). 
2.2. Antifungal Activity 
To carry out the antifungal evaluation, concentrations of naturally occurring drimanes 1–4 and 
semi-synthetic derivatives 5–17 up to 250 µg/mL were incorporated to growth media according to 
CLSI guidelines [11]. Table 1 summarizes the concentration of drimanes that completely inhibited 
(MIC100) the growth of nine opportunistic pathogenic fungi including yeasts (C. albicans,  
C. neoformans, and S. cerevisiae), hialohyphomycetes (Aspergillus spp.) as well as dermatophytes 
(Microsporum and Trichophyton spp). In addition to MIC determinations, the Minimum Fungicidal 
Concentration (MFC) of each active compound against this panel was accomplished by sub-culturing a 
sample of media from MIC tubes showing no growth, onto drug free agar plates (Table 1). 
Table 1. Minimum Inhibitory Concentration (MIC100) and Minimum Fungicidal 
Concentration (MFC) of naturally occurring (1–4) and semi-synthetic (5–17) drimanes, 
against human opportunistic pathogenic fungi. 
Compounds  Yeasts Aspergillus spp Dermatophytes 
Nº Structure  Ca Sc Cn Afum Afl An Mg Tr Tm 
1 
CHO
CHO
H  
MIC100 3.9 15.6 7.8 I I I 62.5 62.5 62.5 
MFC 7.8 31.2 7.8 - - - 125 125 125 
2 
          
MIC100 62.5 62.5 62.5 I I I 62.5 62.5 62.5 
MFC 125 125 125 - - - 125 125 125 
3 
          
MIC100 I I 125 I I I 62.5 62.5 62.5 
MFC - - I - - - 125 125 125 
CHO
CHO
H  
CH2OH
H
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Table 1. Cont. 
4 
O
O
H  
          
MIC100 I 250 I I I I 125 62.5 62.5 
MFC - - - - - - 250 125 125 
5 
           
MIC100 125 250 250 I I I 250 250 250 
MFC - - - - - - 250 250 250 
6 
           
MIC100 250 250 125 I I I 62.5 62.5 62.5 
MFC I I 250 - - - 125 125 125 
7 
           
MIC100 250 250 125 I I I 31.2 31.2 31.2 
MFC I I 250 - - - 125 125 125 
8 
           
MIC100 250 250 125 I I I 62.5 62.5 62.5 
MFC I I 250 - - - 125 125 125 
9 
           
MIC100 250 250 125 I I I 125 125 250 
MFC I I 250 - - - 125 250 250 
10 
H
CH2OH
 
          
MIC100 125 125 31.2 I I I 125 62.5 250 
MFC 250 125 62.5 - - - 250 125 250 
11 
 
           
MIC100 I I I I I I I I I 
MFC - - - - - - - - - 
 
12 
 
MIC100 I I I I I I I I I 
MFC - - - - - - - - - 
13 
 MIC100 I I I I I I 250 250 250 
MFC - - - - - - I 250 250 
14 
  
MIC100 125 125 31.2 I I I 62.5 62.5 125 
MFC 125 125 31.2 - - - 125 125 250 
15  
 
MIC100 I I 250 I I I 250 250 250 
MFC - - - - - - 250 250 250 
CH2OH
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H
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H
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H
H
O
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Table 1. Cont. 
16 
  
MIC100 
 
250 
 
250 
 
250 
 
I 
 
I 
 
I 
 
250 
 
250 
 
250 
MFC I I 250 - - - 250 250 250 
17 
  
MIC100 
 
I 
 
I 
 
I 
 
I 
 
I 
 
I 
 
I 
 
I 
 
I 
MFC - - - - - - - - - 
 
St drugs 
Amph B 
Terbinafine 
Ketoconazole 
 
MIC 0.78 0.50 0.25 0.50 0.50 0.50 0.12 0.075 0.075 
MIC 1.56 3.12 0.39 0.78 0.78 1.56 0.04 0.01 0.025 
MIC 0.5 0.5 0.25 0.12 0.5 0.25 0.05 0.025 0.025 
Ca: Candida albicans ATCC 10231, Sc: Saccharomyces cerevisiae ATCC 9763, Cn: Cryptococcus  
MIC50 (µg/mL) neoformans ATCC 32264; An: Aspergillus niger ATCC 9029, Afu: Aspergillus fumigatus 
ATCC 26934; Afl: Aspergillus flavus ATCC 9170, Mg: Microsporum gypseum C 115; Tr: Trichophyton 
rubrum C113, Tm: Trichophyton mentagrophytes ATCC 9972; Amph B: Amphotericin B. I: inactive  
(MIC > 250 µg/mL). 
Regarding the sensitivity of the different fungi to drimanes, it can be stated that: (i) all compounds, 
but not 11, 12 and 17, exhibited moderate activity (MICs  250 µg/mL) against dermatophytes and 
yeasts; (ii) no member of the series was active against Aspergillus spp; (iii) all active compounds 
showed fungicidal rather than fungistatic properties against most fungi, since they not only inhibit but 
also kill them at Minimum Fungicidal Concentrations (MFC)  250 µg/mL. 
2.3. Structure-Activity Relationships (SAR)  
Since no differences in MICs among the members were observed against dermatophytes  
(one-dilution-step MIC changes are within the range of experimental error) [25], the SAR studies were 
performed on the activity of the series against yeasts (C. albicans, S. cerevisiae and C. neoformans) 
which showed striking differences.  
For a better analysis of the differential behavior of these compounds against yeasts, we selected the 
clinically important fungi C. neoformans and C. albicans as targets. C. neoformans is a fungus that 
remains an important life-threatening complication for immunocompromised hosts, particularly for 
patients who have undergone transplantation of solid organs [26]. Therefore, the activity of compounds 
against this fungus has a true clinical relevance. In turn, C. albicans is one of the leading causes of 
nosocomial blood stream infections worldwide [27]. 
Thus, compounds 1–10, 14–16 that showed activity against at least one yeast were re-tested against 
the standardized strains C. albicans ATCC 10231 and C. neoformans ATCC 32264 determining, this 
time, MIC50 (the minimum concentration of compounds that inhibit 50% of growth), a less stringent 
end-point highly used [27] and recommended by CLSI [10]. MIC50 consistently represent the in vitro 
activity of compounds and many times provide a better correlation with other measurements of 
antifungal activity [27]. Results are shown in Table 2. 
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Table 2. MIC50 values of representative members of the drimane series against C. albicans 
ATCC 10231 (Ca) and C. neoformans ATCC 32264 (Cn). 
MIC50 (µg/mL) 
 Ca Cn LogP 
1 1.9 1.9 2.33 
2 31.2 31.2 2.33 
3 62.5 31.2 3.83 
4 62.5 62.5 3.35 
5 250 250 2.76 
6 62.5 31.2 3.40 
7 62.5 31.2 3.24 
8 31.2 31.2 3.67 
9 250 31.2 2.77 
10 62.5 15.6 3.83 
14 62.5 62.5 3.53 
15 250 I 3.84 
16 31.2 62.5 3.37 
17 I I 4.30 
Amphotericin B 0.78 0.25  
From the analysis of the structures and the activities displayed by all compounds against  
C. albicans and C. neoformans, some structure-activity relationships can be extracted. They were 
grouped according to the influence of each structural feature such as 7,8-double bond in the drimane 
skeleton, configuration of C-9, presence of an aldehyde at C-9 (or at C-8) and presence of an  
α,β-unsaturated aldehyde moiety at C-8. 
2.3.1. Role of the 7,8-Double Bond in the Drimane Skeleton Alone and in α,β Position Respective to 
the Aldehyde on C-8 
The 7,8-double bond in the drimane scheleton appears to be one of the necessary structural features 
for antifungal activity since inactive compounds 11, 12, 13 and 17 all lack this 7,8-double bond. The 
comparison of the activities of 3 with its saturated derivative 17 (devoid of antifungal activity), clearly 
reinforces this observation. A computer-assisted analysis supporting this observation is presented 
below, in Section 2.4. 
In addition, it can be observed that the 7,8-double bond in active structures can be found either 
alone as in compounds 3, 5–10 and 14, or as being part of the C-8 α,β-unsaturated aldehyde moiety 
(constituting a Michael acceptor group) as in compounds 1 and 2. The fact that both drimane structural 
types do display antifungal activity suggests that antifungal drimanes could not act via a Michael 
addition. This finding differs from the antifungal structural requirements of some other sesquiterpenes 
such as the sesquiterpenelactones (+)-costunolide and (−)-dehydrocostunolide isolated from Centaurea 
plants [28] and the synthetic tuberiferin and dehydrobrachylaenolide [29], whose antifungal activities 
were reported to be enhanced by a Michael acceptor group. Nevertheless, our findings are not in any 
way strange since many other diverse structural compounds not containing a Michael acceptor group, 
were found to display strong antifungal properties [30,31].  
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2.3.2. Role of the Configuration of C-9  
The comparison of activities of 1 and 2 shows that, in contrast to Fujita and Kubo’s previous  
report [7], both compounds do possess antifungal activity. However, the 9-derivative 2 displays 16 
and eight times lower activity than its epimer 1, against C. albicans and C. neoformans, respectively. 
This result is consistent with Anke and Sterner’s [8] and Derita et al.’s [2] previous studies, who both 
found that 2 did display antifungal activities, but lower than 1. The different antifungal activities 
displayed by compounds 1 and 2 are supported by their different electronic distributions which are 
presented in Section 2.4.  
2.3.3. Role of an Aldehyde at C-9 and of a CH2OH at C-8 
The presence of an aldehyde group at C-9 appears not to be indispensable for activity, as can be 
observed in compounds 3–7, 9, 10, 15 and 16. Otherwise, the comparison of diol 9 with the 
monoalcohol 10, suggests that a CH2OH at C-8 does not contribute to the activity either. 
2.4. Conformational and Electronic Studies 
To gain a better understanding of the above experimental results, computer-assisted conformational 
and electronic studies were performed on all compounds of the series. The purpose was to obtain 
precise information about the antifungal drimanes’ stereoelectronic characteristics that give support to 
the relationships between structure and activity. 
2.4.1. Conformational Analysis 
For the conformational analysis, each ring of the drimane scheleton was named A and B (Figure 2). 
The essential conformational problem of drimane sesquiterpenes, involves two aspects: 
(a) The conformational behavior of torsional angles 1-5 which determines the spatial ordering of 
ring A. 
(b) The orientation of torsional angles 6-9 which determines the overall shape of ring B. In this 
ring, they are also important torsional angles 10 and 11, which are related to CH2OH 
substituents as R2 or R1.  
Our B3LYP/6311G(d.p) calculations indicated that a chair, and not a boat form, is the energetically 
preferred spatial ordering for ring A in compound 1. The energy gap obtained between both 
conformers is 14.7 Kcal/mol, indicating that this compound is fairly rigid and possesses a restricted 
conformational flexibility. Similar results were obtained for all compounds possessing this structural 
feature like compounds 1–3, 5, 8–10 and 14. Considering that, in these compounds, ring B is a 
cyclohexene, each of the three possible conformations: sofa (also called half-boat), half-chair and boat, 
were evaluated. 
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Figure 2. General representation of drimanes reported here, showing the torsional angles 
that determine the spatial ordering of rings A and B. 
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Our theoretical results indicated that the so-called “half-boat” conformation is the highly preferred 
low-energy form Figure 3a which is in agreement with experimental data obtained for structurally 
related compounds [32–34]. Considering that all these compounds adopt similar low flexible 
conformations, it is clear that this would not be the cause of the different activities displayed against 
fungi. The same can be said for compounds 4, 6 and 7, for which our theoretical calculations indicate 
that the conformational flexibility is even more restricted than the observed for the above compounds 
as a consequence of the presence of a third fused ring. The energetically preferred conformation 
obtained for compound 6 is shown in Figure 3b. Closely similar conformations were obtained for 
compounds 4 and 7. 
Figure 3. Spatial view of the lowest energy conformations obtained for compounds 1 (a) 
and 6 (b) from DFT (B3LYP/6-311G(d,p) optimizations. The chair and half-boat forms 
adopted by rings A and B respectively, may be appreciated in this figure. 
 
Thus, the knowledge of the stereo-electronic properties of these drimanes will surely help to 
elucidate the structural requirements for the antifungal activity. For this analysis, Molecular 
Electrostatic Potentials (MEPs) are particularly valuable, because they allow the visualization and 
assessment of the capacity of a molecule to interact electrostatically with a putative-binding site [35–37]. 
Figure 4 gives the MEPs obtained for compounds 1, 2 and 5, which showed high, moderate and low 
activities respectively. The MEP obtained for 1 (Figure 4a) exhibits three characteristic regions: a clear 
negative minimum value (deep red zone with V(r)min ≈ −0.1139 el/au3) in the vicinity of Δ7,8 double 
bond; a positive region (deep blue zone with V(r)max ≈ 0.1136 el/au3) located near the CH3 group at 
C10; and an extended hydrophobic zone (deep and light green zone with an almost neutral potential 
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V(r)med ≈ −0.0011 el/au3) in the rest of the molecule. Considering that 1 is the most active of the series, 
this MEP should account for the characteristics of the electronic general pattern for all the molecules 
possessing antifungal effect. Interestingly, the MEP obtained for its epimer 2 (Figure 4b), showed a 
marked electronegative zone near the double bond Δ7,8 similar to the showed by 1 but a little smaller. 
In turn, the positive zone is not observed in 2 which is a clear difference with 1. Regarding compound 
5, concomitantly with its lower activity, it showed a red negative zone but considerably smaller than 
that of 2 (Figure 4c). 
Figure 4. Electrostatic potential-encoded electron density surfaces of compounds 1 (a), 2 
(b) and 5 (c). The surfaces were generated using B3LYP/6-311G++(d,p) single point 
calculations. The coloring represents electrostatic potential with red and blue indicating the 
electronegative or the electropositive areas respectively. The color-coded is shown at the 
left, where red is representing the most negative and the blue, the most positive values, 
respectively. Intermediate negative and positive values are represented by colours that 
downgrades from orange to light blue. 
 
For the inactive compounds 13 and 17, the electronegative zone is totally missing (Figure 5). This is 
an expected result considering that these compounds do not possess a double bond in such portion of 
their structures.  
Finally, we calculated logP (the logarithm of the partition coefficient in a biphasic system, e.g.,  
n-octanol/water) for all drimanes which are shown in Table 2. It is known that LogP describes the 
macroscopic hydrophobicity of a molecule, which is a factor related to its ability to penetrate 
membranes of fungal cells and to reach the interacting sites, thus influencing the antifungal activity of 
compounds [38]. LogP values for the different active drimanes of the series varied from 2.33 to 3.84, 
which fall within the range of values observed for other antifungal compounds [31,39,40]. However, 
although these values indicate that they all are lipophilic compounds [39,41], LogP have similar values 
for drimanes with clear different activity, suggesting that this parameter would not have a direct 
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correlation with the antifungal activity of the compounds of Table 2 when acting against C. albicans 
and C. neoformans. 
Figure 5. Molecular Electrostatic Potential (MEPs) obtained for compounds 13 (a) and 17 (b). 
 
Thus, the most active drimane 1 and its epimer 2, both possess the same LogP value = 2.33 yet their 
activity is quite different. The same can be observed for compound 14 which has a LogP = 3.53 and 
displays lower activities. This behavior of drimanes was dissimilar to that of sesquiterpene lactones, 
for which a clear inverse relationship between polarity and antifungal activity was observed [28,29]. 
However, we must take into account that the sesquiterpene lactone skeletons are quite different from 
those of the drimane sesquiterpenes. In addition, different fungal species were used as the test species 
in each work; here, the yeasts C. albicans and C. neoformans were used, while in the previous reports 
the filamentous fungus Cunninghamella echinulata [28] and Phycomyces blakesleeanus were used [29]. 
It has been often observed completely different behaviors for certain compounds towards different type 
of fungi [42]. As the authors stated in [28], there is not much information about the chemical structure-
antifungal activity relationships for sesquiterpenoids and deeper studies should be necessary. In this 
work, we add information that could be useful for a better knowledge of drimane sesquiterpenes 
behavior against human opportunistic and pathogenic fungi. 
3. Experimental 
3.1. Chemistry 
Melting points were determined in a Büchi melting point apparatus and are uncorrected. The 1H- 
and 13C-NMR spectra were run on a Bruker DPX 300 spectrometer operating at 300 and 75 MHz, 
respectively, using chloroform-d as solvent and tetramethylsilane as internal standard. The mass 
spectra were scanned on a Hewlett Packard HP Engine-5989 spectrometer (equipped with a direct inlet 
probe) operating at 70 eV.  
3.1.1. Isolation of Natural Compounds 1–4 
Compounds 1–4 were isolated from DCM extracts of leaves of P. acuminatum Kunth. 
(Polygonaceae) collected on the bank of Coronda River at Puerto Gaboto, Santa Fe Province, 
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Argentina, in March 2010. The plant was identified by Prof. Susana Gattuso and a voucher specimen 
was deposited at the Herbarium of the Vegetal Biology Area of UNR, Suipacha 531, Rosario, 
Argentina (UNR # 2359). The extraction methodology and isolation of pure compounds was 
performed according to reported procedures [1]. Compounds 1–4 were identified by micromelting 
point, optical rotation and spectroscopic data, including 1H- and 13C-NMR [43–47] and were compared 
with authentic samples obtained previously in our laboratory [1,48,49] for polygodial (1) and 
isopolygodial (2) or with literature data [50,51], for drimenol (3) and for confertifolin (4) [44,52]. 
3.1.2. General Procedure for Synthesis of 5 and 6 
To a magnetically well-stirred solution of 1 (2.1 mmol) in MeOH (25 mL) acidified with 5 drops of 
1 M HCl, NaBH4 (8.4 mmol) was added carefully in small portions. The mixture was refluxed at  
50 °C for 4 h and most of the solvent was evaporated in vacuo. Water (20 mL) was added cautiously 
and extractions with EtOAc were performed. The organic phase was dried with MgSO4, evaporated 
and submitted to column chromatography (CC) to give compounds 5 (1.3 mmol) and 6 (0.7 mmol) in 
yields of 62% and 33%, respectively.  
(−)-(5S,10S)-(9R)-7-Drimene-11,12diol (drimendiol) (5): White solid; mp: 74 °C; [α]D25 −8° (CHCl3, c 
= 1.0). IR (film) max 3286, 2924 cm−1. 1H-NMR:  5.78 (1H, m, H-7); 4.33 (1H, d, J = 11.9 Hz,  
H-12B); 4.00–3.90 (4H, m, H-11B, 12A and 2OH); 3.64 (1H, dd, J = 8.7 and 10.4 Hz, H-11A);  
2.15–1.90 (4H, m, H-1β, 6α, 6β and 9); 1.58–1.40 (3H, m, H-2α, 2β and 3β); 1.24–1.10 (3H, m, H-1α, 
3α and 5); 0.88 and 0.86 (6H, 2s, 13-Me and 14-Me); 0.75 (3H, s, 15-Me). 13C-NMR:  136.9 (C-8); 
127.1 (C-7); 67.3 (C-12); 61.2 (C-11); 54.4 (C-5); 49.4 (C-9); 42.0 (C-3); 39.3 (C-1); 35.6 (C-10);  
33.2 (C-13); 32.9 (C-4); 23.5 (C-6); 21.9 (C-14); 18.8 (C-2); 14.5 (C-15). MS m/z (EI): 238 [M+].  
All these data are coincident with the literature [13,16]. 
(−)-(5aS,9aS,9bR)-6,6,9a-Trimethyl-1,3,5,5a,6,7,8,9,9a,9b-decahydronaphtho[1,2-c]furan (6): [α]D25 
−17° (CHCl3, c = 1.0), IR (film) max 2980, 1660, 1460, 1380, 1365 cm−1. 1H-NMR:  5.80 (1H, m,  
H-4); 4.35 (1H, dd, J = 1.1 and 12.0 Hz, H-3β); 3.99 (1H, d, J = 12.0 Hz, H-3α); 3.91 (1H, dd, J = 2.1 
and 10.9 Hz, H-1α); 3.68 (1H, dd, J = 8.3, 10.9 Hz, H-1β); 2.15 (1H, m, H-9b); 2.20–1.20 (9H, m,  
H-9α and β, H-8α and β, H-7α and β, H-5α and β, H-5a); 0.90 and 0.88 (6H, 2s, 12-Me and 11);  
0.77 (3H, s, 10-Me). 13C-NMR:  136.9 (C-3a), 127.4 (C-4); 67.4 (C-3); 61.4 (C-1); 54.4 (C-9b);  
49.4 (C-5a); 42.0 (C-7); 39.3 (C-9); 35.6 (C-9a); 33.2 (C-11); 32.9 (C-6); 23.6 (C-5); 21.9 (C-10); 18.8 
(C-8); 14.5 (C-12). MS m/z (EI): 220 [M+]. This is the first time that this compound is described in detail.  
3.1.3. Synthesis of (−)-(1R,5aS,9aS,9bR)-6,6,9a-Trimethyl-1,3,5,5a,6,7,8,9,9a,9b-decahydro 
naphto[2,1c]furan-1-ol (isodrimeninol, 7) 
Compound 1 (0.55 mmol) was dissolved in MeOH (10 mL) acidified with 3 drops of 1 M HCl and 
NaBH4 (0.27 mmol) was added carefully in small portions. The mixture was stirred during 30 min at  
0 °C and then for 3 h at rt. Water (10 mL) was added cautiously and extractions with EtOAc were 
performed. The organic phase was dried with MgSO4, evaporated and submitted to CC to give 
compound 7 (0.39 mmol) in 71% yield. Colorless oil; [α]D25 −12° (CHCl3, c = 1.0); IR (film) max 
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3400, 1630, 1390, 1370, cm−1. 1H-NMR:  5.52 (1H, m, H-4); 5.29 (1H, brd, J = 2.2 Hz, H-1); 4.50 
(1H, brd, J = 11.3 Hz, H-3β); 4.19 (1H, brd, J = 11.3 Hz, H-3α); 3.04 (1H, brs, -OH); 2.21 (1H, brd,  
J = 2.2, H-9b); 2.13 (1H, m, H-5α); 1.92 (1H, m, H-5β); 1.80 (1H, ddd, J = 2.7, 4.7 and 13.2 Hz,  
H-9β); 1.61 (1H, m, H-8β); 1.49 (2H, m, H-8α and 7β); 1.31 (3H, m, H-5a, 9α and 7α); 0.93; 0.90 (6H, 
2s, 10-Me and 11); 0.83 (3H, s, 12-Me). 13C-NMR:  136.5 (C-3a), 117.1 (C-4), 99.4 (C-1),  
68.9 (C-3), 61.6 (C-9b), 49.8 (C-5a), 42.4 (C-7), 39.8 (C-9), 33.4 (C-9a), 33.1 (C-11), 32.9 (C-6),  
23.6 (C-5), 21.5 (C-10), 18.5 (C-8), 14.0 (C-12). MS m/z (EI): 236 [M+]. All these data agree with the 
literature values [14]. 
3.1.4. Synthesis of (−)-(1R,4aS,8aS)-5,5,8a-Trimethyl-2-vinyl-1,4,4a,5,6,7,8,8a-octahydro naphtalene-
1-carbaldehyde (8) [11]  
Compound 1 (2.14 mmol) was dissolved in anhydrous THF (5 mL), the solution was stirred at 0 °C 
under nitrogen, and Tebbe´s reagent [(C5H5)2TiCH2ClAl(CH3)2] (4 mL of a 0.5M solution in toluene,  
2.0 mmol) was added dropwise. The dark brown solution was allowed to warm to room temperature 
for 10 min, 0.1 M NaOH solution was added (10 drops) and the slurry was filtered through a short pad 
of silica gel. The filtrate was evaporated and purified by CC to give compound 8 as a colorless oil, 
yield 25%; [α]D25 −17° (CHCl3, c = 1.0); IR (film) max 3090, 2720, 1719, 1643, 1607 cm−1. 1H-NMR: 
 9.48 (1H, d, J = 5.1 Hz, CHO); 6.35 (1H, dd, J = 11.2 and 17.9 Hz, Hc); 6.14–6.11 (1H, m, H-3); 
4.93 (1H, d, J = 11.2 Hz, Ha); 4.82 (1H, d, J = 17.9 Hz, Hb); 2.82 (1H, brs, H-1); 2.29–2.19 (2H, m, 
H-4α and β); 1.87–1.81 (1H, m, H-8β); 1.54–1.15 (6H, m, H-8α, H-7α and β, H-6α and β, H-4a); 1.03 
(3H, s, 8a-Me); 0.95 and 0.91 (6H, 2s, 5-Meα and β). 13C-NMR:  206.7 (CHO); 138.5 (=CH);  
132.8 (C-3); 131.5 (C-2); 112.4 (=CH2); 62.6 (C-1); 48.9 (C-4a); 41.9 (C-6); 40.2 (C-8); 37.3 (C-8a); 
33.3 (5-Me); 33.1 (C-5); 24.1 (C-4); 22.3 (5-Me); 18.1 (C-7); 15.5 (8a-Me). MS m/z (EI): 232 [M+]. 
All these data are coincident with the literature [13]. 
3.1.5. Synthesis of (+)-(5S,10S)-(9S)-7-Drimene-11,12diol (isodrimendiol, 9) 
To a magnetically well-stirred solution of 2 (1.06 mmol) in MeOH (20 mL) acidified with 5 drops 
of 1 M HCl, NaBH4 (4.2 mmol) was added carefully in small portions. The mixture was refluxed at  
50 °C for 4 h and most of the solvent was evaporated in vacuo. Water (20 mL) was added cautiously 
and extractions with EtOAc were performed. The organic phase was dried with MgSO4, evaporated 
and submitted to CC to give compound 9 (0.83 mmol) as white solid, yield 78%, mp: 129 °C; [α]D25 
+10° (CHCl3, c = 1.0). IR (film) max 3286, 2924, 1640, 1045 cm−1. 1H-NMR:  5.83 (1H, t, J = 3.5 Hz, 
H-7); 4.13 (1H, d, J = 12.0 Hz, H-12B); 4.00 (1H, d, J = 12.0 Hz, H-12A); 3.92 (1H, dd, J = 4.5 and 
11.0 Hz, H-11B); 3.64 (1H, dd, J = 5.4 and 11.0 Hz, H-11A); 2.60 (2H, brs, 2OH); 2.20–1.90 (3H, m, 
H-6α and β, H-9β); 1.67–1.20 (7H, m, H-1α and β, H-2α and β, H-3α and β, H-5); 0.92 (6H, 2s, 15-Me 
and 14-Me); 0.88 (3H, s, 13-Me). 13C-NMR:  137.2 (C-8); 127.5 (C-7); 67.7 (C-12); 63.1 (C-11); 
54.1 (C-5); 43.4 (C-9); 42.7 (C-3); 36.5 (C-1); 35.9 (C-10); 33.1 (C-4); 33.0 (C-15); 24.3 (C-6); 22.0  
(C-14); 21.7 (C-13); 18.8 (C-2). MS m/z (EI): 238 [M+]. All these data are in agreement with the 
literature values [16]. 
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3.1.6. Synthesis of (+) [(1R,4aS,8aS)-2,5,5,8a-Tetramethyl-1,4,4a,5,6,7,8,8a-octahydro naphthalen-1-
yl]methanol (isodrimenol, 10) 
Diol 9 (0.34 mmol) was dissolved in DCM (15 mL) and catalytic quantities of Pd/C (10% Pd) were 
added. The mixture was left under a hydrogen atmosphere during 4 h and the reaction product was 
filtered, concentrated and purified by CC. Compound 10 (0.29 mmol) was thus obtained in 85% yield; 
[α]D25 +10° (CHCl3, c = 1.0); IR (film) max 3405, 2922, 1620 cm-1; 1H-NMR:  5.57 (1H, m, H-7); 
3.74 (2H, brd, J = 3.0, H-11A and B); 1.74 (3H, brs, 12-Me); 2.10–1.20 (10H, m, H-1α and β, H-2α 
and β, H-3α and β, H-5, H-6α and β, H-9); 0.93 (3H, s, 15-Me); 0.91 and 0.87 (6H, 2s, 13-Me and  
14-Me). 13C-NMR:  131.1 (C-8); 124.6 (C-7); 61.3 (C-11); 57.6 (C-5); 43.4 (C-9); 42.7 (C-3);  
36.8 (C-1); 36.1 (C-10); 33.2 (C-13); 33.0 (C-4); 24.0 (C-6); 23.0 (C-14); 22.2 (C-12); 21.7 (C-2);  
18.8 (C-15). MS m/z (EI): 222 [M+]. All these data are in agreement with the literature [14,17]. 
3.1.7. Synthesis of (−)-7α,8-Epoxy-(9S)-drimane-11,12-diol (11) [20]  
To a solution of diol 9 (4.2 mmols) in CH2Cl2 (30 mL) MCPBA acid (5.4 mmol) was added in 
small portions at rt during 10 min. Stirring was continued at rt for 35 min. The reaction mixture was 
washed with NaHCO3 and water, dried and concentrated. The residue was chromatographed over silica 
gel to afford compound 11 (75% yield); mp: 105 °C; [α]D25 −69° (CHCl3, c = 1.0); IR (film) max 3280, 
3120, 3050 cm−1. 1H-NMR:  3.95–3.45 (4H, m, H-11A and B, H-12A and B); 3.36 (1H, H-7);  
2.1 (1H, dd, J = 4.5 and 15.3 Hz, H-9); 1.74–1.64 (2H, m, H-6α and β); 1.61–1.10 (7H, m H-1α and β, 
H-2α and β, H-3α and β, H-5); 0.96 (3H, s, 15-Me); 0.89 and 0.86 (6H, 2s, 13-Me and 14-Me).  
13C-NMR:  66.6 (C-12); 62.0 (C-8); 60.6 (C-11); 56.8 (C-7); 48.3 (C-9); 42.4 (C-3); 39.0 (C-5);  
36.2 (C-1); 34.9 (C-10); 32.9 (C-15); 32.8 (C-4); 22.8 (C-6); 22.7 (C-14); 22.2 (C-13); 18.3 (C-2). MS 
m/z (EI): 254 [M+]. All these data are in agreement with the literature [20]. 
3.1.8. Synthesis of (−)-(9S)-Drimane-8,11,12-triol (12) [20]  
To a stirred mixture of LiAlH4 (16 mmol) in dry THF (50 mL), a solution of the epoxide 11  
(4.5 mmol) in dry THF (30 mL) was added and the mixture was heated at reflux temperature under 
nitrogen for 4 h. The excess of reagent was decomposed by the addition of EtOAc and an aqueous 
solution of HCl (10%). The mixture was extracted with EtOAc and the organic phase was washed with 
NaHCO3 and water, dried and concentrated to give compound 12 (85% yield); mp: 118 °C; [α]D25 −41° 
(CHCl3, c = 1.0); IR (film) max 3400, 3280, 3120 cm−1. 1H-NMR:  4.0 (2H, m, H-12A and B);  
3.83–3.60 (3H, m, H-11A and B and 1OH); 3.33 (1H, brs, 1OH); 2.58 (1H, brs, 1OH); 1.89 (1H, m,  
H-9); 1.80–1.10 (11H, m, H-1α and β, H-2α and β, H-3α and β, H-5, H-6α and β, H-7α and β);  
1.05 (3H, s, 15-Me); 0.87 and 0.80 (6H, 2s, 13-Me and 14-Me). 13C-NMR:  76.4 (C-8); 69.5 (C-12); 
60.9 (C-11); 56.9 (C-5); 48.6 (C-9); 42.1 (C-3); 37.6 (C-10); 37.4 (C-1); 33.4 (C-4); 33.1 (C-7);  
33.0 (C-15); 23.7 (C-14); 21.8 (C-13); 20.0 (C-6); 18.8 (C-2). MS m/z (EI): 256 [M+]. All these data 
are in agreement with the literature [20]. 
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3.1.9. Synthesis of (−)-11-Hydroxy-(9R)-12-nordriman-8-one (13) [20]  
To a stirred solution of NaIO4 (3.53 mmol) in water (15 mL), a solution of the triol 12 (2.54 mmol) 
in MeOH (10 mL) was added at rt during 1.5 h. The reaction solution was extracted with EtOAc and 
the organic phase was washed with NaHCO3 and water, dried and concentrated to give compound 13 
(90% yield); mp: 112 °C; [α]D25 −22° (CHCl3, c= 1.0); IR (film) max 3280, 1720 cm−1. 1H-NMR:  
3.98 (1H, brd, J = 10 Hz, H-11A); 3.91 (1H, brd, J = 10 Hz, H-11B); 2.36–2.09 (2H, m, 2H-7); 2.37 
(1H, dd, J = 4.3 and 1.8 Hz, H-9β); 2.11 (1H, ddd, J = 1.6, 6.2 and 9.8 Hz, H-7); 1.95 (1H, m, H-7); 
1.70–1.16 (9H, m, H-1α and β, H-2α and β, H-3α and β, H-5, H-6α and β); 0.94 (3H, s, 15-Me); 0.92 
and 0.84 (6H, 2s, 13-Me and 14-Me). 13C-NMR:  214.8 (C-8); 67.0 (C-9); 60.1 (C-11); 46.0 (C-5); 
42.2 (C-3); 40.0 (C-10); 39.3 (C-1); 36.8 (C-7); 33.5 (C-15); 33.4 (C-4); 23.2 (C-6); 22.2 (C-13); 22.0 
(C-14); 18.5 (C-2). All these data agree with the literature values [20]. 
3.1.10. General Procedure for Synthesis of 14 and 15 [13,16]  
A magnetically stirred and cold (0 °C) solution of the alcohol substrate 3 (10 mmol) in acetone  
(50 mL) was titrated with Jones reagent, until the orange-brown color of the reagent persisted for 30 
seconds. The reaction mixture was stirred for an additional 1 h at rt, and then isopropanol (1 mL) was 
added dropwise to destroy any excess of reagent. Water (100 mL) was added, and the suspension was 
extracted with AcOEt, dried with MgSO4, concentrated, and purified by column chromatography to 
give compounds 14 (0.68 mmol) and 15 (0.85 mmol) with yields of 30 and 38%, respectively.  
(−)-(1S,8aS)-2,5,5,8a-Tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalene-1-carbaldehyde (drimenal, 
14): colorless oil, [α]D25 −20° (CHCl3, c = 1.0); IR (film) max 2923, 2851, 1714 cm−1.  
1H-NMR:  9.69 (1H, d, J = 5.1 Hz, H-11); 5.70 (1H, brs, H-7); 2.59 (1H, m, H-9); 2.05 (2H, m, H-6α 
and β); 1.70–1.10 (7H, m, H-1α and β, H-2α and β, H-3α and β, H-5); 1.62 (3H, s, 12-Me); 1.05 (3H, s, 
15-Me); 0.90 and 0.85 (6H, 2s, 13-Me and 14-Me). 13C-NMR:  206.7 (C-11); 127.8 (C-8); 125.5  
(C-7); 67.6 (C-9); 49.1 (C-5); 42.0 (C-3); 40.4 (C-1); 37.0 (C-10); 33.3 (C-14); 33.0 (C-4); 23.7 (C-6); 
22.1 (C-13); 21.6 (C-12); 18.3 (C-2); 15.7 (C-15). MS m/z (EI): 220 [M+]. All these data are in 
agreement with the literature [16,21]. 
(−)-(4aS,8aS)-2,5,5,8a-Tetramethyl-4a,5,6,7,8,8a-hexahydro-4H-naphtalen-1-one (15): white solid; 
mp: 81 °C; [α]D25 −74° (CHCl3, c= 1.0); IR (film) max 2923, 1663 cm−1. 1H-NMR:  6.69–6.67 (1H, 
m, H-3); 2.30–2.25 (2H, m, H-4α and β); 1.89 (1H, brd, J = 13.4 Hz, H-8β); 1.75 (3H, d, J = 2.0 Hz, 
Me-2); 1.70–1.10 (6H, m, H-8α, H-7α and β, H-6α and β, H-4a); 1.04 (3H, s, Me-8a); 0.99 and 0.91 
(6H, 2s, Me-5α and β). 13C-NMR:  205.9 (C-1); 143.4 (C-3); 132.9 (C-2); 49.4 (C-4a); 45.1 (C-8a); 
41.6 (C-6); 33.6 (C-5); 33.2 (C-8); 32.3 (Me-5); 24.4 (C-4); 22.3 (Me-5); 18.2 (C-7); 17.1 (Me-8a); 
16.4 (Me-2). MS m/z (EI): 206 [M+]. All these data are in agreement with the literature [13,16,22]. 
3.1.11. Synthesis of (−)-(4aS,8aS)-3,4a,8,8-Tetramethyl-4a,5,6,7,8,8a-hexahydro-1H-naphtalen-2-one 
(16) [14,17] 
To a magnetically stirred solution of the alcohol substrate 3 (10 mmol) in DCM (50 mL), 
pyridinium chlorochromate (10 mmol) was added. The brown suspension was stirred overnight, until 
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thin layer chromatography analysis showed the disappearance of the starting material. Celite (500 mg) 
and EtOAc (50 mL) were added to the reaction mixture, and the slurry was filtered through a short pad 
of silica gel, washing copiously with EtOAc. The filtrate was dried, evaporated, and purified by 
column chromatography to give compound 16 (1.2 mmol) with 60% yield as a colorless oil; [α]D25 −7° 
(CHCl3, c = 1.0); IR (film) max 2956, 1704, 1673 cm−1. 1H-NMR:  6,39 (1H, d, J = 1.3 Hz, H-4); 
2.49 (1H, dd, J = 3.9 and 17.4 Hz, H-1α); 2.34 (1H, dd, J = 14.0 and 17.4 Hz, H-1β); 1.72 (3H, d,  
J = 1.3 Hz, Me-3); 1.72 (1H, brdd, J = 13.9 and 3.9 Hz, H-5β); 1.70–1.10 (6H, m, H-5α, H-6α and β, 
H-7α and β, H-8a); 1.07 (3H, s, Me-4a); 0.91 (3H, s, Me-8); 0.88 (3H, s, Me-8). 13C-NMR:  201.6  
(C-2); 158.3 (C-4); 131.2 (C-3); 50.6 (C-8a); 41.2 (C-7); 38.4 (C-5); 36.9 (C-4a); 35.4 (C-1);  
32.8 (C-8); 32.2 (Me-8); 20.9 (Me-8); 18.6 (C-6); 18.5 (Me-4a); 15.5 (Me-3). MS m/z (EI): 206 [M+]. 
All these data are in agreement with the literature [13,16,22]. 
3.1.12. Synthesis of (+) [(1S,2S,8aS)-2,5,5,8a-Tetramethyldecahydronaphthalen-1-yl]methanol 
(drimanol, 17) 
Drimenol (3, 0.36 mmol) was dissolved in DCM (10 mL) and catalytic quantities of Pd/C (10% Pd) 
were added. The mixture was left under a hydrogen atmosphere during 4 h and the reaction product 
was filtered, concentrated and purified by CC to obtain compound 17 (75% yield); [α]D25 +15° (CHCl3, 
c = 1.0); IR (film) max 3620, 2950, 1380 cm−1. 1H-NMR:  3.86 (1H, dd, J = 4.5 and 10.7 Hz,  
H-11B); 3.61 (1H, dd, J = 4.5 and 10.7 Hz, H-11A); 2.17 (1H, m, H-8); 1.65–1.10 (12H, m, H-1α and 
β, H-2α and β, H-3α and β, H-5, H-6α and β, H-7α and β, H-9); 0.98 (3H, d, J = 7.5 Hz, 12-Me); 0.88 
and 0.83 (9H, 3s, 13-Me and 15-Me). 13C-NMR:  61.0 (C-11); 56.5 (C-5); 55.7 (C-9); 41.9 (C-3); 
39.9 (C-1); 37.6 (C-10); 34.5 (C-7); 33.6 (C-14); 33.2 (C-4); 28.5 (C-8); 21.6 (C-13); 18.4 (C-6);  
17.5 (C-2); 17.1 (C-15), 15.6 (C-12). MS m/z (EI): 224 [M+]. All these data are in agreement with the 
literature [23]. 
3.2. Antifungal Evaluation 
3.2.1. Microorganisms and Media 
For the antifungal evaluation, standardized strains from the American Type Culture Collection 
(ATCC), Rockville, MD, USA, and CEREMIC (CCC), Centro de Referencia en Micología, Facultad 
de Ciencias Bioquímicas y Farmacéuticas, Suipacha 531 (2000)-Rosario, Argentina, were used in a 
first instance screening: C. albicans ATCC 10231, S. cerevisiae ATCC 9763, C. neoformans ATCC 
32264, A. flavus ATCC 9170, A. fumigatus ATTC 26934, A. niger ATCC 9029, T. rubrum CCC 110, 
T. mentagrophytes ATCC 9972, and M. gypseum CCC 115. 
Strains were grown on Sabouraud-chloramphenicol agar slants for 48 h at 30 °C, maintained on 
slopes of Sabouraud-dextrose agar (SDA, Oxoid), and sub-cultured every 15 days to prevent 
pleomorphic transformations. Inocula of cells or spore suspensions were obtained according to reported 
procedures and adjusted to 1–5 × 103 cells/spores with colony forming units (CFU)/mL [11,12]. 
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3.2.2. Antifungal Susceptibility Testing 
Minimum inhibitory concentration (MIC) of each compound was determined by using broth 
microdilution techniques according to the guidelines of the CLSI for yeasts (M27-A3) and for 
filamentous fungi (M 38 A2) [11,12]. MIC values were determined in RPMI-1640 (Sigma, St. Louis, 
MO, USA) buffered to pH 7.0 with MOPS. Microtiter trays were incubated at 35 °C for yeasts and 
hialohyphomycetes and at 28–30 °C for dermatophytes strains in a moist, dark chamber, and MICs 
were visually recorded at 48 h for yeasts, and at a time according to the control fungus growth, for the 
rest of fungi. 
For the assay, stock solutions of pure compounds were two-fold diluted with RPMI from 250 to 
0.98 µg/mL (final volume = 100 µL) and a final DMSO concentration ≤1%. A volume of 100 µL of 
inoculum suspension was added to each well with the exception of the sterility control where sterile 
water was added to the well instead. Ketoconazole, terbinafine and amphotericin B were used as 
positive controls. 
Endpoints were defined as the lowest concentration of drug resulting in total inhibition (MIC100) of 
visual growth compared to the growth in the control wells containing no antifungal. MIC50 was defined 
as the lowest concentration of a compound that inhibited 50% of the growth control, respectively 
(culture media with the microorganism but without the addition of any compound), and was 
determined spectrophotometrically with the aid of a VERSA Max microplate reader (Molecular 
Devices, Sunnyvale, CA, USA). 
The Minimum Fungicidal Concentration (MFC) of each compound against each strain was also 
determined as follows: After determining the MIC100, an aliquot of 5 µL sample was withdrawn from 
each clear well of the microtiter tray and plated onto a 150-mm RPMI-1640 agar plate buffered with 
MOPS (Remel, Lenexa, KS, USA.). Inoculated plates were incubated at 30 °C, and MFCs were 
recorded after 48 h. The MFC was defined as the lowest concentration of each compound that resulted 
in total inhibition of visible growth. 
3.3. Calculations Methods 
The DFT calculations, full geometry optimization and calculation of the harmonic vibrational 
frequencies were performed using the GAUSSIAN 03 program [53]. Density Functional Theory (DFT) 
calculations were employed in order to properly account for the electron correlation effects. The 
widely employed hybrid method denoted by B3LYP was used, along with the double-zeta split valence 
basis set 6-311G(d,p). This method includes a mixture of HF and DFT exchange terms and the 
gradient corrected correlation functional of Lee, Yang and Parr [54,55], as proposed and parameterized 
by Becke [56,57]. 
A preliminary conformational search was carried out using the GASCOS algorithm [58–60] 
combined with PM6 an RHF/3-21G calculations. All the conformations obtained using this calculations 
were confirmed from B3LYP/6311G(d, p) computations. With any conformational search, it is very 
important to examine the structures obtained to make sure that they are true minima and not transition 
structures or other structures with very low or zero forces on the atoms (stationary points). Thus, minima 
were characterized through harmonic frequency analysis employing B3LYP/6311G(d,p) calculations. 
Molecules 2013, 18 2047 
 
 
The electronic studies were carried out using molecular electrostatic potentials (MEPs) [61]. The 
low-energy conformations were obtained from our conformational search. Subsequently, single point 
calculations were carried out. Thus, these MEPs were calculated using B3LYP/6-311G++(d,p) wave 
functions and MEPs graphical presentations were created using the MOLEKEL program [62]. 
4. Conclusions 
Results obtained here were aimed at contributing to clear up the main structural features necessary 
for the antifungal activity of drimanes (that have been the subject of contradictory statements in the 
literature) by testing them against a unique panel of fungal strains, with a standardized methodology, in 
the same laboratory.  
Regarding the absolute configuration of C-9, here we found that compounds with an aldehyde in 
any of the two possible configurations did possess antifungal activity against C. albicans and  
C. neoformans, although the 9-derivative 2 displays 16 and eight times lower activity than the 9-one 
1. This result is in contrast with Fujita and Kubo [7], but consistent with Anke and Sterner’s [8] and 
Derita et al.’s [2] previous studies, who both found that 2 did display antifungal activities but lower 
than those of compound 1.  
Another result demonstrated that aldehydes at C-9 or C-8 or a CH2OH at C-8 would not be a 
requisite for activity. In addition, this work showed that the 7,8-double bond in the drimane scheleton 
should be considered one of the necessary structural features for antifungal activity, either alone as in 
compounds 3, 5–10 and 14, or as part of a C-8 α,β-unsaturated aldehyde moiety (constituting a 
Michael acceptor group) as in compounds 1 and 2. The fact that both drimane structural types do 
display antifungal activity clearly suggested that antifungal drimanes would not act via a Michael 
addition. This finding differs from Taniguchi’s report [10]. However, as explained in the Introduction, 
the statement of Taniguchi et al. in [10] contradicted their own previous report [7] in which 2  
was shown to be devoid of antifungal activity, although it possessed the ,-unsaturated C-8 aldehyde 
moiety. In addition, results obtained here showed that the electronic characteristics of drimanes play an 
important role in their antifungal behavior. Thus, we found that the electronic distribution in the 
vicinity of the 7,8 is important for activity and also we found that the most active compound 1 
possessed a differential big positive zone in the MEP which could contribute to its high antifungal 
activity. Regarding the influence of the differential hydrophobocity of compounds in the antifungal 
behavior, results showed that variations in LogP values were not reflected in a concomitant variation  
of activity. 
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